Assessment of PeaNoc XL tablet use on patient suffering from chronic pai
Not Applicable
- Conditions
- Health Condition 1: M255- Pain in joint
- Registration Number
- CTRI/2022/10/046693
- Lead Sponsor
- Apex Laboratories Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with DAS 28 (Disease Activity Score) score greater than or equal to
3.2
-Willingness to provide written informed consent to participate in the study.
-Patients understanding the nature and purpose of the study and who are
willing to comply with study procedures.
Exclusion Criteria
-Patients who are taking other NSAID /Pain killers other than standard drug
-Abnormal results on Liver function test
-Patients with diabetic neuropathy
-Patients with severe renal, hepatic, cardiac, gastrointestinal, neurological,
hematological or respiratory disorder
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Hematological investigations: Complete Blood count will be assessed before and after <br/ ><br>the study. <br/ ><br>2. Biochemical investigations: Serum creatinine, Liver function tests will be assessed <br/ ><br>before and after the study. <br/ ><br>3. Inflammatory cytokines (IL-1, IL-6, and TNF-α), C - reactive protein (CRP) and <br/ ><br>Erythrocyte sedimentation rate (ESR) will be assessed before and after the study. <br/ ><br>4. DAS 28 score will be assessed before and after the study.Timepoint: 06 months
- Secondary Outcome Measures
Name Time Method To assess adverse drug reactions during the study period <br/ ><br>Timepoint: 06 months